Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment save search
Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
Published: 2022-01-06 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: 19.47%
H: 3.85%
C: -11.85%
RLFTY | $1.4006 733.33% 100
|
n/a
|
| O: 2.87%
H: 0.0%
C: 0.0%
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -3.39%
H: 6.19%
C: 3.92%
covid-19 treatment fda aviptadil risk covid media submission
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s DiseaseTrial designed to obtain safety and efficacy data of single and multiple dosing regimen
Published: 2022-01-05 (Crawled : 15:30) - biospace.com/
LGVN 1 d | $1.93 -3.98% -4.15% 460K
|
|
| O: 21.84%
H: 0.0%
C: 0.0%
alzheimer treatment phase 2 trial disease cel lomecel-b alzheimer’s alzheimer's designation phase 2b
NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
Published: 2022-01-05 (Crawled : 14:30) - biospace.com/
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: -12.16%
nkt2152 fotivda treatment renal trial therapeutics cel collaboration cell carcinoma
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease
Published: 2022-01-05 (Crawled : 13:30) - globenewswire.com
LGVN 1 d | $1.93 -3.98% -4.15% 460K
|
|
| O: 21.84%
H: 0.0%
C: 0.0%
alzheimer treatment phase 2 trial disease cel lomecel-b alzheimer’s alzheimer's disease alzheimer's phase 2b
Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
Published: 2022-01-05 (Crawled : 12:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: -5.81%
H: 0.0%
C: 0.0%
covid-19 treatment phase 2 phase 2/3 lenzilumab trial covid enroll
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Published: 2022-01-04 (Crawled : 01:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M
|
Health Technology
|
| O: 3.74%
H: 0.0%
C: 0.0%
treatment health diarrhea therapy crofelemer
DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
DXR | $9.74 0.73% 8.3K
|
Health Technology
|
| O: 0.91%
H: 0.81%
C: 0.81%
treatment blood patent technology
Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: -1.54%
H: 1.04%
C: -5.73%
treatment fda gene therapy drug granted preclinical orphan drug therapy biotech iot pre-clinical designation
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: 1.65%
H: 0.4%
C: -5.26%
treatment fda therapeutics cel phase 3 designation
Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment
Published: 2022-01-04 (Crawled : 22:00) - biospace.com/
ANNX | $4.57 2.93% 2.84% 1.2M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: -6.77%
anx005 huntington treatment phase 2 disease bioscience huntington’s disease
Global Hepatorenal Syndrome Treatment Market Research Report (2021 to 2026) - by Type, Treatment, End-user and Region
Published: 2022-01-04 (Crawled : 21:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.57%
H: 1.57%
C: 0.28%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.68%
H: 0.0%
C: 0.0%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 1.01%
H: 0.0%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: 0.0%
EW | $85.94 -0.59% 0.0% 3.9M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
BDX | $234.12 0.42% 0.0% 1.3M
|
Health Technology
|
| O: -0.76%
H: 0.0%
C: 0.0%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: 0.0%
LJPC | $6.22 0.0%
|
Health Technology
|
| O: 0.21%
H: 4.19%
C: -6.06%
CPIX | $1.65 6.02% 790
|
Health Technology
|
| O: -13.36%
H: 0.0%
C: 0.0%
BIVI | $0.4874 -0.21% -0.21% 490K
|
Health Technology
|
| O: 2.86%
H: 12.1%
C: 12.1%
treatment renal research syndros
Amylyx Pharmaceuticals Submits Marketing Authorization Application (MAA) for AMX0035 for the Treatment of ALS
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
AMLX A | $1.88 -5.05% -5.32% 2.5M
|
| Email alert
Add to watchlist
amx0035 treatment als application authorization
Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
NVRO | $12.07 -2.03% 0.0% 390K
|
Health Technology
|
| O: 4.15%
H: 3.5%
C: 0.96%
treatment health thc therapy diabetic diabetes
Global & U.S. CIPN Treatment Markets, 2027 - Calcium Channel A2-Delta Ligands Segment Anticipated to Hold the Largest Share (~34.7%), Owing to High Adoption for the Treatment of CIPN
Published: 2022-01-04 (Crawled : 14:00) - prnewswire.com
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: -1.45%
H: 0.0%
C: 0.0%
treatment
Daxor Awarded New Patent for Blood Volume Guidance Technology to Improve Treatment & Outcomes
Published: 2022-01-04 (Crawled : 13:30) - daxor.com
DXR | $9.74 0.73% 8.3K
|
Health Technology
|
| O: 0.91%
H: 0.81%
C: 0.81%
treatment blood patent technology
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.49%
H: 1.06%
C: -2.49%
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 16.79%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation
U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children
Published: 2022-01-03 (Crawled : 14:30) - biospace.com/
IMMX | $2.21 0.0% 64K
|
|
| O: 98.03%
H: 23.12%
C: -18.01%
imx-110 treatment biopharma drug disease food rare pediatric disease designation cancer children designation rare
Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication
Published: 2022-01-03 (Crawled : 13:00) - biospace.com/
ANEB | $2.85 -7.14% 710
|
Manufacturing
| Email alert
Add to watchlist
aneb-001 treatment phase 2 als
Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
Published: 2022-01-03 (Crawled : 12:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
covid-19 treatment lenzilumab covid pons response
Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
Published: 2022-01-03 (Crawled : 12:00) - biospace.com/
BNOX | $0.98 -1.17% 14K
|
n/a
|
| O: 0.0%
H: 0.0%
C: -0.38%
bnc210 treatment phase 2 order social anxiety disorder
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.